Eton Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- 126.2
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | $37.60M | $0.35 | $0.43 |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | $24.30M | $0.05 | $0.14 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 19, 2026 | After market close | $21.30M | $0.05 | $0.19 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $22.50M | $-0.07 | $0.04 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | $18.90M | $-0.10 | $0.03 |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | $17.30M | $-0.06 | $0.07 |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 18, 2025 | Before market open | $11.60M | $-0.02 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $10.30M | $0.02 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 13, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| adjusted gross marginnon-GAAP | full year 2026 | 70% | Maintained |
| Adjusted EBITDA marginnon-GAAP | 2026 | 35% | Raised |
| R&D expenses | full year | $10.00M to $14.00M | – |
| revenue | 2026 | $145.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Eton Pharmaceuticals filed with the SEC
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO ® (miltefosine) Capsules
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI ® (hydrocortisone) Oral Solution
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Eton Pharmaceuticals relaunches HEMANGEOL ® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces CFO Succession Plan
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces U.S. FDA Approval for
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces Addition to Russell 2000 ® and Russell 3000 ® Indexes
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces U.S. FDA Approval for
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Out-Licenses International Rights to Increlex ®
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE ® for Phenylketonuria
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
Other events · EX-99.1 to Form 8-K
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K